Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
- Live webcast presentation on Wednesday, September 22nd at 10:45 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through...
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
- Solid clinical and operational execution demonstrated with advancement of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with commencement of pivotal study (TransportNPC™) and start of commercial-scale manufacturing - Progression of Phase...
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
- Data seen to-date in the ongoing Phase 1 extension study provide additional support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1 ("NPC")- Favorable safety...
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Company to discuss clinical progress of Trappsol® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage...
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Global clinical protocol agreed upon by US Food and Drug Administration (FDA) and European MedicinesAgency (EMA) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...
Cyclo Therapeutics Announces Launch of New Website
- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence site...
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from...
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
Live video webcast presentation with members of the Company's executive leadership team on Thursday, June 17th at 12:30 PM ETGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...